



number.

PTO/SB/21 (03-03)  
Approved for use through 4/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	
Total Number of Pages in this Submission	6
<b>ENCLOSURES (check all that apply)</b>	

- Fee Transmittal Form
- Fee Attached
- Amendment/Reply
- After Final
- Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

- Drawing(s)
- Licensing-related Papers
- Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s) \_\_\_\_\_

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please identify below):  
20-references

Remarks

#### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name      HOWSON AND HOWSON  
Cathy A. Kodroff

Signature

Date      November 26, 2003      11/26/03

#### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name

Signature

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1 -800-PTO-9199 (1-800-786-9199) and select option 2.

Customer No. 00270



SS15AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

) Group Art Unit:

Andersen et al

) Examiner:

Appln. No. 10/617,038

)

Filed: July 11, 2003

) HAND-DELIVERED

For: THERAPEUTIC TB VACCINE

) November 26, 2003

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B are attached and a copy of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Customer No. 00270

## REMARKS

Listed below are previously filed, co-pending, related U.S. patent applications. These applications and the present application are commonly owned: Copies of applications and claims are enclosed.

- (1) U.S. Patent Application No. 09/310,551, filed May 12, 1999, US Patent No. 6,649,170, issued on November 18, 2003  
US Patent Application No. 10/654,720, filed September 3, 2003
- (2) U.S. Patent Application No. 10/217,787, filed August 13, 2002, publication No. US-2003-0036638-A1, February 20, 2003

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicant

By   
Cathy A. Kodoroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Phone: (215) 540-9200  
Fax: (215) 540-5818

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/617,038
				Filing Date	July 11, 2003
				First Named Inventor	Andersen et al
				Group Art Unit	
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	SSI5AUSA

**OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	D	<b>SAMBROOK ET AL</b> , molecular cloning, A laboratory manual, Cold Spring Harbor Laboratories, NY, (1989) XP-002091112	
	E	Anon. Global Tuberculosis Control, WHO Report. (2001)	
	F	<b>BRANDT ET AL</b> , ESAT-6 Subunit Vaccination against <i>Mycobacterium Tuberculosis</i> , Infection and Immunity, Vol. 68, No. 2, pp. 791-795 (Feb. 2000)	
	G	<b>BOON ET AL</b> , Journal of Bacteriology, Vol. 183, No. 8 pp. 2672-2676, (April 2001)	
	H	<b>DOHERTY ET AL</b> , Immune Responses to the <i>Mycobacterium Tuberculosis</i> -Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients, Journal of Clinical Microbiology, Vol. 40, No. 2, pp. 704-706, (February 2002)	
	I	<b>FLORCZYK ET AL</b> , Identification and Characterization of Mycobacterial Proteins Differentially Expressed under Standing and Shaking Culture Conditions, Including Rv2623 from a Novel Class of Putative ATP-Binding Proteins, Infection and Immunity, Vol. 69, No. 9, pp. 5777-5785, (September 2001)	
	J	<b>HARBOE ET AL</b> , B-Cell Epitopes and Quantification of the ESAT-6 Protein of <i>Mycobacterium Tuberculosis</i> , Infection and Immunity, Vol. 66, No. 2, pp. 717-723, (February 1998)	
	K	<b>MANGANELLI ET AL</b> , The <i>Mycobacterium Tuberculosis</i> ECF Sigma Factor $\sigma^E$ : Role in Global Gene Expression and Survival in Macrophages, Molecular Microbiology, Vol. 41, No. 2, pp. 423-437, (May 2001)	
	L	<b>MONAHAN ET AL</b> , Differential Expression of Mycobacterial Proteins Following Phagocytosis by Macrophages, Microbiology, 147, pp. 459-471, (2001)	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/617,038
				Filing Date	July 11, 2003
				First Named Inventor	Andersen et al
				Group Art Unit	
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	SSI5AUSA

**OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/row number(s), publisher, city and/or country where published	T <sup>2</sup>
	M	RAVN ET AL, Human T Cell Responses to the ESAT-6 Antigen from Mycobacterium Tuberculosis, The Journal of Infectious Diseases, 179, pp. 637-45, (1999)	
	N	ROSENKRANDS ET AL, Identification and Characterization of a 29-Kilodalton Protein from Mycobacterium Tuberculosis Culture Filtrate Recognized By Mouse Memory Effector Cells, Infection and Immunity, Vol. 66, No. 6, pp. 2728-2735, (June 1998)	
	O	ROSENKRANDS ET AL, Hypoxic Response of Mycobacterium Tuberculosis Studied by Metabolic Labeling and Proteome Analysis of Cellular and Extracellular Proteins, Journal of Bacteriology, Vol. 184, No. 13, pp. 3485-3491, (July 2002)	
	P	SHERMAN ET AL, Regulation of the Mycobacterium Tuberculosis Hypoxic Response Gene Encoding $\alpha$ -Crystallin, PNAS, Vol. 98, No. 13, pp. 7534-7539, (June 19, 2001)	
	Q	SKJØT ET AL, Comparative Evaluation of Low-Molecular-Mass Proteins from Mycobacterium Tuberculosis Identifies Members of the ESAT-6 Family as Immunodominant T-Cell Antigens, Infection and Immunity, Vol. 68, No. 1, pp. 214-220, (January 2000)	
	R	VORDERMEIER ET AL, Correlation of ESAT-6-Specific Gamma Interferon Production with Pathology in Cattle Following Mycobacterium Bovis BCG Vaccination against Experimental Bovine Tuberculosis, Infection and Immunity, Vol. 70, No. 6, pp. 3026-3032, (June 2002)	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**